212Pb-TCMC-HuIgG

212Pb-TCMC-HuIgG is a **radioimmunoconjugate** used primarily as a non-specific control in preclinical and experimental studies involving radioimmunotherapy. It consists of purified human immunoglobulin G (HuIgG) conjugated with TCMC (1,4,7,10-tetra-(2-carbamoylmethyl)-cyclododecane), and radiolabeled with the alpha-emitting isotope lead-212 (212Pb)[11]. Unlike targeted therapeutics such as 212Pb-TCMC-trastuzumab, which directs alpha radiation to HER2-expressing cells, 212Pb-TCMC-HuIgG lacks tumor specificity and acts via non-targeted delivery of highly cytotoxic alpha particle radiation to surrounding cells[1][5][7][11]. Its mechanism of action is based on the induction of DNA double-strand breaks, apoptosis, and cell cycle arrest (notably G2/M), resulting from the cytotoxic effects of 212Pb-generated alpha particles within proximity to treated cells; however, as a non-targeted antibody, effects are generally considered non-specific[1][7][11]. This agent is not intended for therapeutic use but rather as a control to distinguish targeted effects in experimental setups.

Brand names

212Pb-TCMC-HuIgG

Other names

lead Pb 212 TCMC-HuIgG